Dupixent Shows Meaningful Progress in Treating Bullous Pemphigoid
Regeneron Pharmaceuticals, Inc. and Sanofi have shared pivotal clinical data pointing to the potential of Dupixent (dupilumab) as a treatment for moderate-to-severe bullous pemphigoid (BP). In this investigational setting, Dupixent delivered consistent benefits that stood out against placebo and highlighted a path beyond the limits of traditional steroid-heavy care.
Inside the ADEPT Trial: What Met the Mark
The ADEPT study reached its primary and secondary endpoints. Patients receiving Dupixent were about five times more likely to achieve sustained disease remission than those on placebo: 20% versus 4% (p=0.0114). That difference—modest in number but meaningful in lived experience—signals a clinically relevant effect for a notoriously hard-to-manage disease.
What “Sustained Remission” Meant in This Study
Sustained remission required complete clinical remission with successful tapering of oral corticosteroids by week 16, followed by no relapses and no need for rescue therapy during the next 36 weeks of treatment. In addition to remission itself, the study documented clear improvements in itch and overall disease control.
Efficacy Highlights That Matter to Patients
Beyond overall remission, Dupixent performed well on measures that track day-to-day stability and flare prevention. After tapering off corticosteroids, 59% of patients on Dupixent had no disease relapse, compared with 16% on placebo (p=0.0023). And 42% of people on Dupixent avoided any rescue therapy, versus 12% in the placebo group (p=0.0004). In short: fewer flares, fewer rescue interventions.
Secondary Endpoints: Depth and Durability of Control
Secondary outcomes reinforced the primary findings, showing both stronger disease control and symptom relief:
- 41% of patients on Dupixent achieved a 90% or greater reduction in disease severity, compared with 10% on placebo (p=0.0003).
- 40% reported a clinically meaningful reduction in itch severity, versus 11% on placebo (p=0.0006).
- Days in complete remission without corticosteroids averaged 40 with Dupixent, compared with 13 on placebo (p=0.0072).
Why These Results Could Shift Care
BP is chronic, painful, and often disabling. Itch can be relentless; lesions can get infected. Against that backdrop, a therapy that improves remission and lowers relapse risk—while helping patients taper steroids—could change everyday care. George D. Yancopoulos, M.D., Ph.D., a key leader in this research, highlighted how these data signal a potential step forward for people living with the harsh realities of BP.
Safety and Tolerability: What Was Observed
Overall adverse event rates were similar between Dupixent and placebo groups. Some side effects—such as peripheral edema and arthralgia—were reported more often with Dupixent. No deaths occurred in the Dupixent arm during the trial, while two occurred in the placebo group. These findings underscore the need to keep monitoring safety over time, especially in a vulnerable population, while recognizing the signals observed here.
What Comes Next for Dupixent
Given the strength of the ADEPT results, the case for regulatory review is clear. If approved, Dupixent could become the first targeted therapy specifically for BP. That would mark a meaningful shift away from reliance on broad immunosuppression and toward a more precise approach to disease control.
About Dupixent and Its Broader Program
Dupixent is a fully human monoclonal antibody developed with Regeneron’s VelocImmune technology. It targets the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, aiming to control inflammation without suppressing the immune system. This selective mechanism is central to its potential across allergic and inflammatory conditions.
Research continues to evaluate Dupixent in additional chronic diseases influenced by similar pathways. Regeneron and Sanofi remain focused on expanding where the medicine can help, guided by ongoing clinical results and careful, stepwise evidence generation.
Frequently Asked Questions
What is Dupixent used for?
Dupixent is used to treat certain inflammatory conditions such as asthma and eczema, and it now shows promise as an investigational option for bullous pemphigoid based on the ADEPT trial results.
How does Dupixent work?
Dupixent is a monoclonal antibody that targets the IL-4 and IL-13 pathways. By blocking these drivers of type 2 inflammation—and without broadly suppressing the immune system—it helps reduce disease activity.
What did the ADEPT trial show in BP?
Dupixent increased sustained remission rates to 20% versus 4% on placebo (p=0.0114). It also reduced relapse after steroid taper (59% vs. 16%, p=0.0023) and lowered the need for rescue therapy (42% vs. 12%, p=0.0004), with additional gains in itch and overall disease severity.
What does “sustained remission” mean here?
In ADEPT, sustained remission meant complete clinical remission with steroid taper by week 16, followed by no relapses and no rescue therapy for the next 36 weeks of treatment.
Is Dupixent approved for bullous pemphigoid?
Not yet. Based on these findings, the therapy is a candidate for regulatory evaluation. If approved, it may become the first targeted treatment specifically for BP.
